Validation of Cirrhosis Risk Score in Patients with Chronic Hepatitis C

Investigators:

Anna S. Lok, MD
Hongjin Huang, PhD, Celera

Hypotheses/Aims

Genetic factors play a role in fibrosis progression and adverse clinical outcomes (hepatic decompensation and hepatocellular carcinoma [HCC]) in patients with hepatitis C.

Primary Aims

1. To validate the Caucasian cirrhosis risk score (CRS) in predicting the risk of cirrhosis in HALT-C non-Hispanic Caucasian patients and to evaluate the accuracy of the Caucasian CRS in predicting the risk of progression from advanced fibrosis to cirrhosis and the risk of development of cirrhosis complications.
2. To evaluate the Caucasian CRS in predicting the risk of cirrhosis and cirrhosis complications in HALT-C African American patients.

Secondary Aims

1. To validate the African American CRS (when available) in HALT-C African American patients.
2. To evaluate the combined utility of CRS and non-invasive indices of hepatic fibrosis such as AST-platelet ratio index (APRI) and the HALT-C cirrhosis prediction index.